Current Clinical Trials
For more information about any of the clinical trials listed
below, call the Clinical Trials Office at 860-679-4384.
IRB Number
|
Title of Clinical Trial
|
Principal Investigator
|
|
05-61-1 |
NSABP R-04: Rectal Study – “A Clinical Trial
Comparing Preoperative Radiation Therapy and
Capecitabine with our without Oxaliplatin with
Preoperative Radiation Therapy and Continuous
IV Infusion (CVI) of 5-FU with or without
Oxaloplatin in the Treatment of Patients with
Operable Carcinoma of the Rectum” |
Bruce Brenner, M.D. |
| 07-175-3 |
NSABP B-40: Breast Cancer – “Randomized
Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating
the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel
when Administered Before AC with or without
Bevacizumab and Correlative Science Studies
Attempting to Identify Predictors of High Likelihood
for pCR with Each of the Regimens” |
Bruce Brenner, M.D. |
|
07-264-3 |
Optical Coherence Tomography (OCT) and MicroPET for Imaging of the Ovary |
Molly Brewer, M.D. |
|
06-163-1 |
Excel Study: Prevention Trial – “A Phase III Randomized Study of Exemestane
vs. Placebo in Postmenopausal Women at Increased Risk of Developing Breast
Cancer” Learn more > |
Molly Brewer, M.D. |
|
06-560-1 |
ECOG: (PACCT-1): Tailorx Breast “Program
for the Assessment of Clinical Cancer Testa
(PACCT-1) Trial Assigning Individuals Options
for Treatment: The TAILORx Trial” |
Susan Tannenbaum, M.D. |
| 07-88-1 |
NSABP B-42: Breast Cancer – “A Clinical Trial
to Determine the Efficacy of Five Years of
Letrozole Compared to Placebo in Patients Completing
Five Years of Hormonal Therapy Consisting of an
Aromatase Inhibitor (AI) or Tamoxifen Followed by
an AI in Prolonging Disease-free Survival in
Postmenopausal Women with Hormone Receptor
Positive Breast Cancer” |
Susan Tannenbaum, M.D. |
|
07-68-3 |
Connecticut Breast Health Initiative Study Mental and
Physical Stressors in the Diagnosis of Breast Cancer.
A multidisciplinary analysis of distress and systemic
biomarkers in patients referred for biopsy of a suspected
breast cancer lesion. |
Susan Tannenbaum, M.D. |
|
07-043-2 |
Bone Health Study – Medications for breast cancer such as anastrozole (Arimidex)
or letrozole (Femara) are often used for the treatment of breast cancer.
These medications lower the levels of the female hormone estrogen, and as a
result may result in bone loss and increased risk of fractures. We are
studying the early effects of this treatment on bone health. Benefits for
participants include monitoring of their bone health during the first year
of treatment with anastrozole or letrozole. If you, or someone you know,
is considering taking anastrozole (Arimidex) or letrozole (Femara) and would
like to know more about participation in this research study, please contact
the principle investigator, Dr. Pamela Taxel at 860-679-4743. |
Pamela Taxel, M.D. |
Oral Mucositis Trials
For more information about the oral mucositis trials below, call
Linda Choquette, R.D.H., C.C.R.P., at 860-679-3918.
|
